Bladder Cancer, Cancer of Unknown Primary, Colorectal Cancer, Head and Neck Cancer, Ovarian Cancer, Sarcoma, Solid Neoplasm, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage III Pancreatic Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer
Conditions
Brief summary
This phase I trial studies the side effects and best dose of palbociclib with cisplatin or carboplatin in treating patients with solid tumors that have spread to other places and usually cannot be cured or controlled with treatment. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving palbociclib with cisplatin or carboplatin may help stop tumor growth in patients with advanced solid tumors.
Detailed description
PRIMARY OBJECTIVES: I. Assess the safety and tolerability of palbociclib when administered along with cisplatin or carboplatin. II. Establish the recommended phase 2 dose (RP2D) of the tested combinations. SECONDARY OBJECTIVES: I. Characterize the pharmacokinetic (PK) profiles of cisplatin, carboplatin. II. Obtain preliminary evidence of anti-tumor efficacy of the tested combination regimens. III. Conduct PK/pharmacodynamics (PD) correlative analyses using palbociclib trough concentration and cyclin-dependent kinase 4 (CDK4) inhibition read-outs in tumor and surrogate samples collected on course 1 day 22 (C1D22). IV. Assess potential association between tissue-based biomarkers and efficacy. OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 2 arms. ARM A: Patients receive cisplatin intravenously (IV) over 30-60 minutes on day 1 and palbociclib orally (PO) once daily (QD) on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive carboplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for up to 4 weeks.
Interventions
DRUGCarboplatin
Given IV
DRUGCisplatin
Given IV
DRUGPalbociclib
Given PO
Sponsors
Pfizer
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Emory University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed solid organ malignancy * Patients enrolled in the expansion cohort must have histologically or cytologically confirmed squamous non-small cell lung cancer (NSCLC), breast or pancreaticobiliary tract cancer * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥ 20 mm (≥ 2 cm) with conventional techniques or as ≥ 10 mm (≥ 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam * Leukocytes ≥ 3,000/mL * Absolute neutrophil count ≥ 1,500/mL * Platelets ≥ 100,000/mL * Hemoglobin ≥ 10 g/dL * Total bilirubin ≤ 1.5 × institutional upper limit of normal (except for patients with Gilbert disease) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/ alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≤ 2.5 × institutional upper limit of normal (up to 5 X upper limit of normal \[ULN\] for patients with liver metastasis) * Creatinine within normal institutional limits OR creatinine clearance ≥ 60 mL/min/1.73 m² for patients with creatinine levels above institutional normal * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after completion of study drug administration * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients who have had cytotoxic anticancer chemotherapy or immune checkpoint inhibitor within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or palliative radiation within 2 weeks (stereotactic radiation therapy \[SRS\] for brain metastasis within 48 hours) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier * Patients receiving cytotoxic agent as immunomodulatory therapy for a non neoplastic indication (e.g. methotrexate for rheumatoid arthritis) and who are unable to discontinue such agents within 2 weeks prior to starting treatment * Oral targeted therapy within five days or five half-lives, whichever is longer, prior to initiating protocol therapy treatment * Patients who are receiving any other investigational agents * Use of strong cytochrome P450, family 3, subfamily A (CYP3A) inhibitors and inducers * Patients with symptomatic uncontrolled brain metastases are excluded; (patients with stable treated or asymptomatic untreated brain metastasis not requiring glucocorticoids are allowed) * History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, carboplatin or cisplatin * Concurrent administration of strong inducers and inhibitors of CYP3A enzyme or CYP3A substrates with narrow therapeutic window * Uncontrolled intercurrent illness including, but not limited to: * Ongoing or active infection requiring intravenous antibiotics at the time of treatment initiation * Symptomatic congestive heart failure (requiring hospital stay within the last 6 months) * Myocardial infarction within the last 6 months * Unstable angina pectoris, cardiac arrhythmia * Psychiatric illness * Social situations or circumstances that would limit compliance with study requirements * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with palbociclib * Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 | Study completion, an average of 2 years |
| Incidence of dose limiting toxicities defined as grade 3 or higher toxicity | Up to 4 weeks |
| Recommended phase 2 dose (RP2D) as the highest doses of palbociclib and cisplatin or palbociclib and carboplatin | Study completion, an average of 2 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (complete response + partial response) assessed by Response Evaluation Criteria in Solid Tumors 1.1 criteria | Up to 3 years | Will be summarized and presented along with 95% exact confidence intervals. |
| Pharmacokinetic (PK) characteristics of carboplatin including maximum concentration (Cmax) | Up to 4 weeks | Within-subject and between-cohort comparisons of Cmax will be performed using Wilcoxon (non-parametric) test. |
| Pharmacokinetic (PK) characteristics of cisplatin including maximum concentration (Cmax) | Up to 4 weeks | Within-subject and between-cohort comparisons of Cmax will be performed using Wilcoxon (non-parametric) test. |
Countries
United States
Outcome results
None listed